Psychosis and Catatonia in Fragile X Syndrome

Mitra Keshtkarjahromi 1, Karishma Palvadi 2, Aayush Shah 2, Kendall Dempsey 2, Silvina Tonarelli 2

1. Psychiatry, University of Maryland, Baltimore, USA 2. Psychiatry, Texas Tech University Health Sciences Center El Paso, El Paso, USA

Corresponding author: Karishma Palvadi, karishma.palvadi@ttuhsc.edu

Abstract

Fragile X syndrome is an inherited disorder with an X-linked dominant inheritance pattern that is the most commonly inherited cause of intellectual developmental disorder and has a strong association with autism spectrum disorder. This report describes the case of an 18-year-old male with fragile X syndrome and multiple psychiatric comorbidities who presented with new onset psychosis and catatonia.

Introduction

Fragile X syndrome (FXS) is the most commonly inherited cause of intellectual developmental disorder (IDD) and is commonly associated with autism spectrum disorder (ASD) [1-3]. The syndrome has an X-linked dominant inheritance pattern and results from a full mutation (>200 CGG repeats) in the fragile X mental retardation 1 (FMR1) gene located on Xq27.3.2. The FMR1 gene encodes a protein named the fragile X mental retardation protein (FMRP), which is essential for normal brain development. Healthy individuals have 6-54 repeats of the CGG sequence in the 5' untranslated region of the FMR1 gene [4]. When an individual carries an intermediate number of CGG repeats (55-200) excess FMR1 mRNA is produced and this is considered a pre-mutation allele. The pre-mutation is responsible for fragile X-associated tremor ataxia syndrome (FXTAS), fragile X-associated premature ovarian insufficiency (FXPOI), and fragile X-associated neurological disorders [5-9]. In FXS, the number of CGG repeats exceeds 200, and there is a lack of FMRP causing down-regulation of the gamma-aminobutyric acid (GABA) A and B receptors and up-regulation of metabotropic glutamate receptors 5 (mGluR5) [10,11]. Males are usually more severely affected by FXS because the affected gene (FMR1) is located on the X chromosome. The typical phenotype of a patient with FXS includes a long face, prominent ears, hyperextensible joints, and post-pubertal macroorchidism [3]. The syndrome is commonly associated with psychiatric disorders such as attention deficit hyperactive disorder (ADHD), learning disorders, obsessive-compulsive disorder, depression, anxiety, and language function disorders [1,2,9,12-16].

Catatonia is a treatable neuropsychiatric syndrome characterized by abnormal movements, which occurs mainly in the context of an underlying general medical or psychiatric disorder including mood disorders, schizophrenia, and ASD. According to the Diagnostic and Statistical Manual (DSM) for Psychiatric Disorders, 5th edition, the clinical diagnosis of catatonia requires at least three of the following symptoms: stupor (no psychomotor activity), catalepsy (maintaining a passively induced posture), waxy flexibility (slight, even resistance to positioning by the examiner), mutism, negativism (opposition or no response to external stimuli), posturing (spontaneous and active maintenance of a posture against gravity), mannerisms, stereotypes, agitation, grimacing, echolalia, or echopraxia [17]. The underlying neurochemical mechanism of catatonia is similar to the mechanism seen in FXS including GABA hypoactivity and glutamate hyperactivity. However, dopamine dysfunction, a common mechanism of catatonia, is seen in a majority of FXS leading to ADHD during childhood and Parkinsonism symptoms in the elderly [11,15]. The treatment plan usually includes the correction of the underlying disorder; however, benzodiazepines and electroconvulsive therapy (ECT) can also be used as an effective treatment [8,16].

There is a 2.5% risk of developing malignant catatonia and development of neuroleptic malignant syndrome when anti-psychotics are used for the treatment of catatonia [15,18]. Malignant catatonia has a considerable risk of mortality due to cardiovascular instability, nutritional deficiency, functional impairment, and multi-organ failure related complications.

Case Presentation

An 18-year-old Caucasian male with FXS, ADHD, IDD, and ASD diagnosed in childhood was referred by his pediatric neurologist to the psychiatric clinic for evaluation of sudden onset psychosis, catatonia, and behavioral changes. The patient was diagnosed with FXS at birth. Due to having a severe global developmental delay, he was enrolled in an early intervention program and a special education program at his school. The patient has four other siblings, two of his older brothers have FXS and ADHD. The patient’s
mother is a carrier for the FMR1 gene and has diagnoses of ADHD, anxiety, and depression. The maternal grandfather was also diagnosed with FXS. The patient’s father has a history of bipolar disorder type 1 and post-traumatic stress disorder. In the month prior to psychiatric evaluation, the patient presented with agitation, aggressiveness, and anger towards family members leading to the patient being isolated in his room. Irritability, insomnia, crying spells, and mood swings were also present. Auditory and visual hallucinations were reported. The patient was seeing people around him and he was talking to them. He also had a fear of someone being behind his back. The patient experienced a loss of basic learned skills including holding a pen, writing, and drawing.

Catatonia including standing in one position with limited movements and limited blinking, staring at the ceiling for prolonged periods of time, waxy flexibility, posturing, stereotypies, echolalia, mutism, and cogwheel rigidity were noticed. According to his parents, the patient used to be a "sweet, friendly boy" who now is "a very different kid" who is very difficult to manage at home.

Before the psychiatric evaluation, the patient was hospitalized for 12 days in a medical hospital. Vital signs were normal. On neurological examination, severe cog-wheel rigidity in all extremities, bilateral downward-pointing toes, bilateral hands clenched in flexed position, and stiffness with rigidity of the entire body were noted. During the hospital course, all the labs and imaging were normal as can be seen in Table 1. Treatment included a benzodiazepine challenge test, quetiapine, and diphenhydramine with no improvements. The patient was discharged with outpatient psychiatric follow-up.

| Labs/Imaging                                      | Results       |
|---------------------------------------------------|---------------|
| Complete Blood Count                              | Normal        |
| Complete Metabolic Panel                          | Normal        |
| Thyroid Stimulating Hormone                       | Normal        |
| Estimate Sedimentation Rate                       | Normal        |
| C-Reactive Protein                                | Normal        |
| Urine Drug Screening                              | Normal        |
| Blood Toxicology                                  | Normal        |
| Electroencephalography x2                         | Normal        |
| Brain and Spinal Magnetic Resonance Imaging       | Normal        |
| Abdominal Computerized Tomography                 | Normal        |
| Electrocardiography                               | Sinus Tachycardia |

**TABLE 1: Results of Diagnostic Testing**

**Course and treatment**

On his first visit to the psychiatric clinic, the patient had been taking quetiapine 150 mg daily and lorazepam 4 mg daily for 30 days without any improvement. On examination, patient was noted to have cog-wheel rigidity, muscle stiffness, and dystonia. He was internally stimulated, and his mood and affect were irritable and anxious. Lack of cooperation and rapport was seen. He was complaining of low back pain due to severe dystonia in his back and chest.

Lorazepam was changed to clonazepam 1 mg twice a day per oral, divalproex sodium 250 mg per day was started, and quetiapine was continued.

On his two-week follow-up, the patient had mild improvement, but he was still isolated from the family due to aggression. Due to the patient’s continued symptoms, the patient’s mother decided to initiate lisdexamfetamine 50 mg daily from patient’s older brother’s prescription, which significantly improved the patient’s aggressive behavior. She felt comfortable making this change as she has two other children with the same diagnoses; however, she did report this medication change immediately and has been compliant with her sons’ medications after this with no concern for abuse. She was counseled at the follow-up appointment that lisdexamfetamine is a Schedule II substance and should not be started without consultation with a physician. Due to the improvement of symptoms, the dose of divalproex sodium was titrated up to 1000 mg daily and clonazepam was decreased to 0.5 mg twice daily, while quetiapine 150 mg daily and lisdexamfetamine 50 mg daily were continued as before.
At his four-week follow-up, the patient was on the combination of lisdexamfetamine, divalproex sodium, quetiapine, and clonazepam 2 mg daily with marked improvements in psychosis, catatonia, behavioral change, aggression, irritation, and insomnia. His parents reported that the patient was back to his normal self. The patient was no longer isolated from his family and was participating in social activities with them. On physical and mental examination, there were no signs of dystonic positioning, but mild cog-wheel rigidity continued to be noted in the upper extremities. The patient was following commands and had good eye contact with appropriate aet.

The patient continues to be monitored at the psychiatric clinic regularly and has not had a recurrence of symptoms.

**Discussion**

FXS has a variety of comorbidities including ADHD, ASD, IDD, and other neuropsychiatric disorders (depression, anxiety, etc.). Psychosis is seen in less than 10% of those with FXS. Catatonia can be present in FXS if it is comorbid with ADHD, ASD, IDD or any other mood disorder, but there is not enough data to support exclusive relationship between the two. The underlying mechanism of catatonia has been identified due to changes in three hormonal activities. These include dopamine hypoactivity, GABA hypoactivity, and glutamate hyperactivity [11,15]. Moreover, the comorbidity between FXS and the development of ADHD in early childhood has been shown to be due to dopamine dysfunction.

Catatonia is increasingly recognized at a rate of 4%-17% in adolescents and adults with ASD [8]. Although the diagnosis of catatonia in ASD is clinical, it may be further supported by a benzodiazepine challenge test, which is known to result in marked and temporary improvement.

The association of catatonia and ADHD is a rare condition and the data published about this association is scarce. The symptoms of excited catatonia can overlap with the symptoms of ADHD, as research has shown improvement in hyperactivity, impulsivity, and inattention with lorazepam [12].

On the other hand, the association between bipolar disorder and catatonia is well known and ECT is an effective treatment used mainly for patients resistant to benzodiazepines [19]. Therefore, it is crucial to consider bipolar disorder in the differential diagnosis in pediatric patients with a diagnosis of ADHD who develop catatonia [20].

Catatonia is a complex condition that is characterized by dysfunction in the regulation of multiple neurotransmitters. There is no standardized pharmacological treatment plan for this heterogeneous condition; however, benzodiazepines and ECT remain the most effective treatment at this time. The literature reported a case study of a 25-year-old male with a history of FXS, who developed psychosis and catatonia which were refractory to multiple medications. In that case study, the patient’s catatonia improved with ECT; however he later developed cognitive decline [15]. The current report highlights the association of multiple psychiatric comorbidities in a patient with FXS and the response to a combination of psychotropic medications.

**Conclusions**

This is an unusual case report of a patient with FXS and multiple psychiatric comorbidities who presented with new onset catatonia and psychosis. The exact etiology of the catatonia in this case is unclear (secondary to ADHD, IDD, FXS, ASD, or mood disorder); however, the patient had a good response to the combination of divalproex sodium, lisdexamfetamine, quetiapine, and clonazepam. These medications were used to treat the most likely causes of the catatonia.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Hagerman RJ, Harris SW: Autism profiles of males with fragile X syndrome. Am J Ment Retard. 2008, 113:427-438. 10.1352/2008.113:427-438
2. Hagerman RJ, Protic D, Rajaratnam A, Salcedo-Arellano MJ, Aydin EY, Schneider A: Fragile X-associated neuropsychiatric disorders (FXAND). Front Psychiatry. 2018, 9:564. 10.3389/fpsyt.2018.00564
3. Turner G, Robinson H, Laing S, Goddard A, Partington M: Population screening for fragile X. Lancet. 1992,
339:1210-1213. 10.1016/0140-6736(92)91142-u
4. Wenzel HJ, Murray KD, Haify SN, et al.: Astroglial-targeted expression of the fragile X CGG repeat premutation in mice yields RAN translation, motor deficits and possible evidence for cell-to-cell propagation of FXATAS pathology. Acta Neuropathol Commun. 2019, 7:27. 10.1186/s40478-019-0677-7
5. Bear MF, Huber KM, Warren ST: The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27:570-577. 10.1016/j.tins.2004.04.009
6. Jacquesmonet S, Pacini I, Jench AE, et al.: Protein synthesis levels are increased in a subset of individuals with fragile X syndrome. Hum Mol Genet. 2018, 27:2059-2051. 10.1093/hmg/ddy999
7. Loomis EW, Eid JS, Peluso P, et al.: Sequencing the unsequenceable: expanded CGG-repeat alleles of the fragile X gene. Genome Res. 2013, 23:121-128. 10.1101/gr.141705.112
8. Chandrasekar T, Copeland N, Spanos M, Sikich L: Autism, psychosis, or both? unraveling complex patient presentations. Child Adolesc Psychiatr Clin N Am. 2020, 29:103-113. 10.1016/j.chc.2019.08.003
9. Salcedo-Arellano MI, DuFour B, McLennan Y, Martinez-Cerdeno V, Hagerman R: Fragile X syndrome and associated disorders: clinical aspects and pathology. Neurobiol Dis. 2020, 136:104740. 10.1016/j.nbd.2020.104740
10. Paluszkiewicz SM, Martin BS, Huntsman MM: Fragile X syndrome: the GABAergic system and circuit dysfunction. Dev Neurosci. 2011, 33:549-564. 10.1159/000329420
11. Heulens I, D’Hulst C, Van Dam D, De Deyn PP, Kooy RF: Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav Brain Res. 2012, 229:244-249. 10.1016/j.bbr.2012.01.031
12. Farzin F, Perry H, Hessl D, et al.: Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr. 2006, 27:157-144. 10.1097/00004703-200604002-00012
13. Schneider A, Johnston C, Taxone F, et al.: Broad autism spectrum and obsessive-compulsive symptoms in adults with the fragile X premutation. Clin Neuropsychol. 2016, 30:929-945. 10.1080/13854046.2016.1189556
14. Tan MM, Dy JB, Salcedo-Arellano MI, Taxone F, Hagerman R: Fragile X-associated neuropsychiatric disorders: a case report. Future Neurol. 2019, 14:10.2217/fnl-2018-0040
15. Winarni TJ, Schneider A, Ghaziuddin N, Seritan A, Hagerman RJ: Psychosis and catatonia in fragile X: case report and literature review. Intractable Rare Dis Res. 2015, 4:139-146. 10.5582/irdr.2015.01028
16. Salcedo-Arellano MI, Hagerman RJ, Martinez-Cerdeño V: Fragile X syndrome: clinical presentation, pathology and treatment. Gac Med Mex. 2020, 156:60-66. 10.24875/GMM.19002575
17. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). American Psychiatric Pub, Washington, D.C.; 2013. 10.1176/appi.books.9780890425596
18. Rosebush PI, Mazurek MF: Catatonia and its treatment. Schizophr Bull. 2010, 36:239-242. 10.1093/schbul/sbp141
19. Medda P, Toni C, Luchini F, Mariani MG, Mauri M, Perugi G: Catatonia in 26 patients with bipolar disorder: clinical features and response to electroconvulsive therapy. Bipolar Disord. 2015, 17:892-901. 10.1111/bdi.12548
20. Mehta A, Carlton E, Franco K: Catatonia in adolescence: a case report. Psychiatry (Edgmont). 2008, 5:37-41.